Is Biophytis S.A. (BPTS) a Buy, Sell, or Hold?
NASDAQ : BPTS
Biophytis S.A.
$8.22 USD
-$1.28 (-13.47%)
- Volume
- 17.95K
- Average Volume
- 9.66K
- Market Capitalization
- $2.61M
- P/E Ratio
- -0.58
- Dividend Yield
- 0.00%
- Price Target
- $15.00
- Year High
- $168.80
- Year Low
- $8.05
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.72
Company Overview
NASDAQ
Stanislas Veillet
Biotechnology
Healthcare
BPTS
22
FR
USD
Liquidity Metrics
-2.14
0.72
0.72
0.45
0.00
Sales & Valuation
-$
0.00
-2.54
-0.18
-9.65
Profitability
-$12.54
-$17.03M
0.00%
0.00%
593.65%
-142.36%
P/E Metrics
-0.58
-0.01
-0.01
Analyst Price Target & Rating
$15.00
$15.00
$15.00
0/5
1 Analysts
-45.20%
Financial Health Scores
-13.38
2/9
-$8.35M
$8.71M
$15.13M
-$30.07M
Key Metrics (TTM)
$4.99M
0.00
-0.36
0.72
593.65%
-285.79%
-174.24%
-572.96%
-2451 days
Company Executives
| Name | Title |
|---|---|
| Pierre J. Dilda | Chief Scientific Officer |
| Rene Lafont | Scientific Advisor & Member of Scientific Advisory Board |
| Rob van Maanen | Chief Medical Officer |
| Edouard Bieth | Chief Business Officer |
| Nicolas Fellmann | Chief Financial Officer |
| Waly Dioh | Chief Clinical Operating Officer |
| Chiara Baccelli | Chief Pharmaceutical Operations Officer & Quality Assurance Director |
| _ Teylan | Financial Controller |
| Stanislas Veillet | Chairman of the Board & Chief Executive Officer |
Poll Results
No votes yet today — be the first to share your view!
About Biophytis S.A. (NASDAQ:BPTS) Stock
Biophytis S.A. operates as a clinical-stage biotechnology firm dedicated to advancing therapeutic solutions aimed at decelerating degenerative processes and enhancing functional outcomes for individuals grappling with age-related illnesses. These therapies function by targeting and stimulating critical biological resilience pathways, which are designed to offer protection against and counteract the detrimental effects of various biological and environmental stressors contributing to age-associated pathologies. The company's flagship pharmaceutical candidate is Sarconeos (BIO101), an orally administered small molecule currently under development for addressing a spectrum of neuromuscular conditions, notably sarcopenia and Duchenne muscular dystrophy (DMD). Additionally, it is progressing th ... rough a Phase 2/3 clinical study to treat severe respiratory compromise in patients afflicted with COVID-19. Biophytis is also developing Macuneos (BIO201), another oral small molecule intended for ophthalmic disorders such as dry age-related macular degeneration (AMD) and Stargardt disease. In a collaborative effort, Biophytis SA has partnered with AFM-Telethon specifically for the advancement of Sarconeos (BIO101) in the context of DMD treatment. Established in 2006, the company maintains its corporate headquarters in Paris, France.
Frequently Asked Questions
-
What is the current Biophytis S.A. (BPTS) stock price?
-
Biophytis S.A.(NASDAQ:BPTS) stock price is $8.22 in the last trading session. During the trading session, BPTS stock reached the peak price of $168.8 while $8.05 was the lowest point it dropped to. The percentage change in BPTS stock occurred in the recent session was --13.47% while the dollar amount for the price change in BPTS stock was -$1.28.
-
BPTS's industry and sector of operation?
-
The NASDAQ listed BPTS is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BPTS?
-
Pierre J. Dilda | Chief Scientific Officer
Rene Lafont | Scientific Advisor & Member of Scientific Advisory Board
Rob van Maanen | Chief Medical Officer
Edouard Bieth | Chief Business Officer
Nicolas Fellmann | Chief Financial Officer -
How many employees does BPTS have?
-
Number of BPTS employees currently stands at 22. BPTS operates from Sorbonne University, Paris, None 75005, FR.
-
Link for BPTS official website?
-
Official Website of BPTS is: https://www.biophytis.com
-
How do I contact BPTS?
-
BPTS could be contacted at phone #33 1 44 27 23 00 and can also be accessed through its website. BPTS operates from Sorbonne University, Paris, None 75005, FR.
-
How many shares of BPTS are traded daily?
-
The average number of BPTS shares traded daily for last 3 months was 9.66K.
-
What is the market cap of BPTS currently?
-
The market value of BPTS currently stands at $2.61M with its latest stock price at $8.22